Zhonghong Pulin Medical Products (300981) Fundamentals 2026 — Revenue Analysis | SniperIQ
Zhonghong Pulin Medical Products (300981) is a CN-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of ¥4.3B, trading at ¥10.03 on the SHZ. This SniperIQ fundamentals page covers Zhonghong Pulin Medical Products's valuation, profitability (net margin -5.4%), revenue (¥2.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Zhonghong Pulin Medical Products's market cap?
Zhonghong Pulin Medical Products (300981) has a market capitalization of approximately ¥4.3B, trading at ¥10.03 on the SHZ. Market cap moves with the live share price.
What is Zhonghong Pulin Medical Products's P/E ratio?
Zhonghong Pulin Medical Products's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 0.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Zhonghong Pulin Medical Products?
Zhonghong Pulin Medical Products runs a net profit margin of -5.4%, a gross margin of 11.4%, and an operating margin of -6.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Zhonghong Pulin Medical Products generate?
Zhonghong Pulin Medical Products reported revenue of ¥2.4B for fiscal year 2025, with net income of -¥112M and earnings per share (EPS) of -0.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Zhonghong Pulin Medical Products pay a dividend?
Zhonghong Pulin Medical Products offers a trailing dividend yield of about 3.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Zhonghong Pulin Medical Products financially healthy?
Zhonghong Pulin Medical Products carries a debt-to-equity ratio of 0.19x and a current ratio of 2.32x, with a market beta of 0.48. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Zhonghong Pulin Medical Products a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Zhonghong Pulin Medical Products (300981) the key facts are: market cap ¥4.3B, revenue ¥2.4B, 52-week range 9.21-18.87. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Zhonghong Pulin Medical Products's full fundamentals live
Get Zhonghong Pulin Medical Products's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.